



DR ALAN ROBERTSON BSc PhD
Chief Executive Officer, Pharmaxis Ltd



Dr Alan Robertson has been the CEO of Pharmaxis Ltd since its first venture capital investment in December 1999 and has been instrumental in building the company to its present position. Pharmaxis listed on the ASX in 2003 and on the NASDAQ in 2005. Before becoming the full time CEO of Pharmaxis, he was the CEO of Promics, (now part of Cephalon) and led a cardiovascular drug discovery team at Kinacia. Before that Dr Robertson spent 6 years with Amrad (now part of CSL) and 2 years with Faulding (now Hospira).

Dr Robertson has a PhD in chemistry from Glasgow University and has been actively involved in the discovery, development and marketing of various compounds, including new treatments for migraine and cardiovascular disease. Alan is the inventor of the migraine therapeutic Zomig, which is marketed worldwide by AstraZeneca.